RecruitingPhase 3NCT04856488
Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter
Sponsor
Jan Calissendorff
Enrollment
182 participants
Start Date
Nov 18, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to assess if preoperative treatment with Lugol's solution prior to thyroidectomy can reduce the surgical complications hypoparathyroidism and laryngeal nerve palsy
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria2
- Hyperthyroidism accepted for thyroidectomy due to toxic nodular goiter with free T4 \<30 pmol/L or Graves' disease
- Signed informed consent
Exclusion Criteria17
- Unstable coronary artery disease
- Previous thyroid surgery
- Congestive heart failure
- Renal insufficiency
- Hepatic failure
- Current infection
- Treatment with steroids or anticoagulants
- Thyroid associated orbitopathy CAS \> 2
- Diabetes mellitus type 1
- Active cancer
- Severe psychiatric illness
- Amiodarone treatment
- Pregnancy
- Breast feeding
- Women of child bearing potential not using contraceptive
- Inability to comprehend the meaning of the study
- Iodine hypersensitivity
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGIodine-Potassium Iodide 5%-10% Oral and Topical Solution
Iodine Potassium Iodide 5% oral solution, administered 3 times per day for 10 days
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04856488